Clinical Trials | August 26, 2024
Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Subscribe To Our Newsletter & Stay Updated
